To investigate whether the inhibitory effect of BTLA-stimulated DCs on the development of Th17 and Th1 cells was mediated by modulating the expression of co-stimulatory molecules, agonistic anti-BTLA antibody-treated DCs and control DCs from the ocular BD patients and normal controls were analyzed for CD83, CD80, CD86, CD40 and HLA-DR expression by flow cytometry. Here, BTLA is linked to Behcet disease.